Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares fell 1.8% on Monday . The stock traded as low as $35.38 and last traded at $35.48. Approximately 181,388 shares changed hands during mid-day trading, an increase of 262% from the average daily volume of 50,104 shares. The stock had previously closed at $36.12.
Neoleukin Therapeutics Stock Performance
The firm’s 50-day moving average is $36.88 and its two-hundred day moving average is $29.88. The stock has a market cap of $330.90 million, a P/E ratio of -11.32 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc was a clinical-stage biotechnology company focused on developing computationally designed protein therapeutics for cancer and other serious diseases. The company was headquartered in Seattle, Washington, and operated primarily in the United States.
Its lead program was NL-201, an engineered cytokine designed to mimic the activities of interleukin-2 and interleukin-15. Neoleukin investigated NL-201 as an immunotherapy intended to stimulate immune cells that can recognize and attack tumors, including in patients with advanced solid cancers.
Read More
- Five stocks we like better than Neoleukin Therapeutics
- The Ultimate Cyber Shield: CrowdStrike Rises Past $235
- Palantir Just Told Wall Street Where AI Infrastructure Is Headed
- Homebuilders Are Down for the Year, Is Wall Street in Denial?
- Turning Trash to Cash: A $129M Bet on Waste
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
